Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid

植物源生物碱优先靶向结肠癌的机制

基本信息

  • 批准号:
    8447422
  • 负责人:
  • 金额:
    $ 38.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-04-01 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): One of the main challenges in cancer therapy is the excessive toxicity of chemotherapeutics due to their nonselective activity. One strategy to preferentially target cancer cells is to utilize agents that preferentially kill cells lacking p53.We have recently identified a plant-derived alkaloid that has seen clinical use primarily for neurological disorders that can preferentially induce death in colon cancer cells in the absence of p53. This compound induces cell death in p53-null cells by inducing the expression of a p53 family member, p73, which activates apoptosis. Interestingly, in the presence of p53, p73 is not induced by this alkaloid and cells undergo a p53- dependent cell cycle arrest that protects them from apoptosis. In this proposal we aim to assess 1) the unique regulation of p73 by this natural compound 2) mechanisms through which this agent induces apoptosis and 3) the clinical potential of this agent for colon cancer using mouse xenograft studies. Not only will this proposal provide biological insights into novel mechanisms that modulate p73 but it may also lead to a new use of an existing therapeutic agent for colon cancer therapy.
描述(由申请人提供):癌症治疗的主要挑战之一是化疗药物的非选择性活性导致的过度毒性。一种优先靶向癌细胞的策略是利用优先杀死缺乏p53的细胞的药物。我们最近鉴定了一种植物来源的生物碱,其主要用于神经系统疾病,可以在缺乏p53的情况下优先诱导结肠癌细胞死亡。该化合物通过诱导p53家族成员p73的表达来诱导p53缺失细胞中的细胞死亡,p73激活细胞凋亡。有趣的是,在p53的存在下,p73不被这种生物碱诱导,细胞经历p53依赖性细胞周期阻滞,保护它们免于凋亡。在这项提案中,我们的目的是评估1)这种天然化合物对p73的独特调节,2)这种药物诱导细胞凋亡的机制,3)使用小鼠异种移植研究这种药物治疗结肠癌的临床潜力。这一提议不仅将为调节p73的新机制提供生物学见解,而且还可能导致现有治疗剂用于结肠癌治疗的新用途。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Wald其他文献

David Wald的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Wald', 18)}}的其他基金

HTS for the discovery of activators of NK cell cytotoxicity
HTS 用于发现 NK 细胞毒性激活剂
  • 批准号:
    10631030
  • 财政年份:
    2021
  • 资助金额:
    $ 38.07万
  • 项目类别:
HTS for the discovery of activators of NK cell cytotoxicity
HTS 用于发现 NK 细胞毒性激活剂
  • 批准号:
    10372203
  • 财政年份:
    2021
  • 资助金额:
    $ 38.07万
  • 项目类别:
HTS for the discovery of activators of NK cell cytotoxicity
HTS 用于发现 NK 细胞毒性激活剂
  • 批准号:
    10184729
  • 财政年份:
    2021
  • 资助金额:
    $ 38.07万
  • 项目类别:
Targeting metabolism in AML
AML 中的靶向代谢
  • 批准号:
    10514584
  • 财政年份:
    2020
  • 资助金额:
    $ 38.07万
  • 项目类别:
Targeting metabolism in AML
AML 中的靶向代谢
  • 批准号:
    10293585
  • 财政年份:
    2020
  • 资助金额:
    $ 38.07万
  • 项目类别:
Targeting metabolism in AML
AML 中的靶向代谢
  • 批准号:
    10013953
  • 财政年份:
    2020
  • 资助金额:
    $ 38.07万
  • 项目类别:
ShEEP Request for an X-Ray Irradiation System
ShEEP 请求 X 射线辐照系统
  • 批准号:
    10177392
  • 财政年份:
    2020
  • 资助金额:
    $ 38.07万
  • 项目类别:
NK Cell Therapy of Human Colorectal Cancer.
人类结直肠癌的 NK 细胞疗法。
  • 批准号:
    10162737
  • 财政年份:
    2019
  • 资助金额:
    $ 38.07万
  • 项目类别:
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid
植物源生物碱优先靶向结肠癌的机制
  • 批准号:
    8295154
  • 财政年份:
    2012
  • 资助金额:
    $ 38.07万
  • 项目类别:
Mechanisms of preferential targeting of colon cancer by a plant-derived alkaloid
植物源生物碱优先靶向结肠癌的机制
  • 批准号:
    8651428
  • 财政年份:
    2012
  • 资助金额:
    $ 38.07万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 38.07万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 38.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 38.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 38.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 38.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 38.07万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 38.07万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 38.07万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 38.07万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 38.07万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了